Event

The management of severe eosinophilic asthma patients who also exhibit an allergic phenotype is an important clinical question for physicians. To address this issue, this industry theatre will discuss a meta-analysis of mepolizumab use in patients eligible for omalizumab focusing on relevant biomarkers that may or may not be useful in predicting response in these patients with an overlapping phenotype. This will be followed by a discussion of new clinical data from the OSMO study that included patients with an overlapping phenotype not optimally controlled with omalizumab therapy. Together, this information will help physicians in their treatment decisions for severe eosinophilic asthma patients with an overlapping phenotype.